Aoife McMahon
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Aoife McMahon has a total of 363 co-authors. Here are the top co-authors by number of shared publications:
- Helen Parkinson
EMBL-EBI
11 shared publications - Joannella Morales
European Molecular Biology Laboratory, European Bioinformatics Institute (EMBL-EBI), Cambridge, UK
11 shared publications - Fiona Cunningham
European Molecular Biology Laboratory, European Bioinformatics Institute, Wellcome Genome Campus, Hinxton, Cambridge CB10 1SD, UK
10 shared publications - Laura Wiseman Harris
EMBL-EBI
7 shared publications - Laurent Gil
British Heart Foundation Cardiovascular Epidemiology Unit, Department of Public Health and Primary Care, University of Cambridge, Cambridge, UK
7 shared publications - Maria Cerezo
European Molecular Biology Laboratory, European Bioinformatics Institute , Wellcome Genome Campus , Hinxton , Cambridge CB10 1SD
7 shared publications
Latest Publications
- Open Access
Predicted Effector Gene Aggregation, Standards and Unified Schema (PEGASUS): A Community Framework for Effector Gene Reporting
Genome-wide association studies (GWAS) increasingly report predicted effector genes (PEGs) - genes hypothesised to mediate the biological effects of associated variants. These function as key outputs for advancing variant-to-function research, mechanistic understanding, and therapeutic discovery. However, the rapid growth of PEG lists has not been matched by standards for organising, annotating, and reporting these predictions. As shown by recent landscape analyses, PEG lists vary widely in methodology, evidence definition, nomenclature, provenance tracking, and data structure, limiting interoperability, benchmarking, reuse, and adherence to FAIR principles. To address this gap, we convened an international multi-stakeholder community comprising method developers, data generators, resource maintainers, curators, funders, journal editors, and downstream users. Through a 2024 workshop and a 2025 working group series, we developed the Predicted Effector Gene Aggregation, Standards and Unified Schema (PEGASUS) framework. PEGASUS specifies (i) a metadata standard to capture provenance, trait and GWAS descriptors, evidence sources, and integration methods; (ii) a structured evidence matrix reporting all genes and all evidence underpinning prioritisation at each locus; and (iii) a concise PEG list that summarises author-prioritised genes linked transparently to underlying evidence. The framework balances transparency, machine readability, burden on submitters, and alignment with existing community standards. PEGASUS provides the first community-developed schema for reporting predicted effector genes and their supporting evidence. Adoption of this framework by authors will improve the comparability, reproducibility, and reusability of PEG outputs across studies, facilitating more robust biological inference, enabling cross-resource comparison of gene-prioritisation methods to support community benchmarking, and integration into downstream resources and analytical pipelines. PEGASUS-compliant data can be shared via the PEG Data Registry platform (https://kpndataregistry.org/peg), promoting re-use and establishing the basis for future integration with publicly shared GWAS data.
Open AccessPredicted Effector Gene Aggregation, Standards and Unified Schema (PEGASUS): A Community Framework for Effector Gene Reporting
Genome-wide association studies (GWAS) increasingly report predicted effector genes (PEGs) - genes hypothesised to mediate the biological effects of associated variants. These function as key outputs for advancing variant-to-function research, mechanistic understanding, and therapeutic discovery. However, the rapid growth of PEG lists has not been matched by standards for organising, annotating, and reporting these predictions. As shown by recent landscape analyses, PEG lists vary widely in methodology, evidence definition, nomenclature, provenance tracking, and data structure, limiting interoperability, benchmarking, reuse, and adherence to FAIR principles. To address this gap, we convened an international multi-stakeholder community comprising method developers, data generators, resource maintainers, curators, funders, journal editors, and downstream users. Through a 2024 workshop and a 2025 working group series, we developed the Predicted Effector Gene Aggregation, Standards and Unified Schema (PEGASUS) framework. PEGASUS specifies (i) a metadata standard to capture provenance, trait and GWAS descriptors, evidence sources, and integration methods; (ii) a structured evidence matrix reporting all genes and all evidence underpinning prioritisation at each locus; and (iii) a concise PEG list that summarises author-prioritised genes linked transparently to underlying evidence. The framework balances transparency, machine readability, burden on submitters, and alignment with existing community standards. PEGASUS provides the first community-developed schema for reporting predicted effector genes and their supporting evidence. Adoption of this framework by authors will improve the comparability, reproducibility, and reusability of PEG outputs across studies, facilitating more robust biological inference, enabling cross-resource comparison of gene-prioritisation methods to support community benchmarking, and integration into downstream resources and analytical pipelines. PEGASUS-compliant data can be shared via the PEG Data Registry platform (https://kpndataregistry.org/peg), promoting re-use and establishing the basis for future integration with publicly shared GWAS data.
- Open Access
- 22 January 2026
- Published by Springer Nature in Research Square
A resource of “bottom-line” variant associations for 1,281 complex traits by integrating data across published genome-wide association studies
Through an analysis of 2,602 genome-wide association studies (GWAS) across 830 human traits, we find that most (56% of) well-studied traits have at least two published GWAS, and many (29%) have at least five. We show that the lack of an established approach for adjudicating variant association estimates across multiple published studies can lead to uncertainty and invalid inferences: using all associations ever published for a trait increases true positives (by 12%) but also false positives (by 55%) relative to using associations from the largest published GWAS for the trait. We employ a “bottom-line” procedure for meta-analyzing published GWAS while inferring and accounting for sample overlap, which identifies a more accurate and comprehensive list of associations relative to existing approaches. Five commonly used bioinformatic methods for post-GWAS analyses produce reliable results when applied to the bottom-line associations. We present these results for 1,281 human complex traits, including 1,839 single-ancestry and 576 trans-ancestry analyses, for browsing or download via the NHGRI Association to Function Knowledge Portal. This resource of “consensus” GWAS results is intended to increase replicability, reuse, and interpretation of GWAS and downstream analyses.
- 22 January 2026
- Published by Springer Nature in Research Square
Open AccessA resource of “bottom-line” variant associations for 1,281 complex traits by integrating data across published genome-wide association studies
Through an analysis of 2,602 genome-wide association studies (GWAS) across 830 human traits, we find that most (56% of) well-studied traits have at least two published GWAS, and many (29%) have at least five. We show that the lack of an established approach for adjudicating variant association estimates across multiple published studies can lead to uncertainty and invalid inferences: using all associations ever published for a trait increases true positives (by 12%) but also false positives (by 55%) relative to using associations from the largest published GWAS for the trait. We employ a “bottom-line” procedure for meta-analyzing published GWAS while inferring and accounting for sample overlap, which identifies a more accurate and comprehensive list of associations relative to existing approaches. Five commonly used bioinformatic methods for post-GWAS analyses produce reliable results when applied to the bottom-line associations. We present these results for 1,281 human complex traits, including 1,839 single-ancestry and 576 trans-ancestry analyses, for browsing or download via the NHGRI Association to Function Knowledge Portal. This resource of “consensus” GWAS results is intended to increase replicability, reuse, and interpretation of GWAS and downstream analyses.
- 29 May 2025
- Published by Springer Nature in Nature Genetics
- Vol. 57 (7) , 1578-1587
Realizing the promise of genome-wide association studies for effector gene prediction
Genome-wide association studies (GWAS) identify regions of the genome in which genetic variation is associated with the risk of complex diseases, such as diabetes, or the magnitude of traits, such as blood pressure. Determining which ‘effector genes’ mediate the effects of GWAS associations is essential to using GWAS to understand disease mechanisms and develop new therapies. In recent years, GWAS authors have increasingly included effector gene predictions as part of their study results. However, the research community has not yet converged on standards for generating or reporting these predictions. In this Perspective, we illustrate the diversity of the evidence types used to support effector gene predictions and argue for future initiatives to increase their accessibility and usefulness.
- 29 May 2025
- Published by Springer Nature in Nature Genetics
- Vol. 57 (7) , 1578-1587
Realizing the promise of genome-wide association studies for effector gene prediction
Genome-wide association studies (GWAS) identify regions of the genome in which genetic variation is associated with the risk of complex diseases, such as diabetes, or the magnitude of traits, such as blood pressure. Determining which ‘effector genes’ mediate the effects of GWAS associations is essential to using GWAS to understand disease mechanisms and develop new therapies. In recent years, GWAS authors have increasingly included effector gene predictions as part of their study results. However, the research community has not yet converged on standards for generating or reporting these predictions. In this Perspective, we illustrate the diversity of the evidence types used to support effector gene predictions and argue for future initiatives to increase their accessibility and usefulness.
- Top Cited PapersOpen Access
- 12 November 2024
- Published by Oxford University Press (OUP) in Nucleic Acids Research
- Vol. 53 (D1) , D998-D1005
The NHGRI-EBI GWAS Catalog: standards for reusability, sustainability and diversity
The NHGRI-EBI GWAS Catalog serves as a vital resource for the genetic research community, providing access to the most comprehensive database of human GWAS results. Currently, it contains close to 7 000 publications for >15 000 traits, from which more than 625 000 lead associations have been curated. Additionally, 85 000 full genome-wide summary statistics datasets—containing association data for all variants in the analysis—are available for downstream analyses such as meta-analysis, fine-mapping, Mendelian randomisation or development of polygenic risk scores. As a centralised repository for GWAS results, the GWAS Catalog sets and implements standards for data submission and harmonisation, and encourages the use of consistent descriptors for traits, samples and methodologies. We share processes and vocabulary with the PGS Catalog, improving interoperability for a growing user group. Here, we describe the latest changes in data content, improvements in our user interface, and the implementation of the GWAS-SSF standard format for summary statistics. We address the challenges of handling the rapid increase in large-scale molecular quantitative trait GWAS and the need for sensitivity in the use of population and cohort descriptors while maintaining data interoperability and reusability.
- 12 November 2024
- Published by Oxford University Press (OUP) in Nucleic Acids Research
- Vol. 53 (D1) , D998-D1005
Top Cited PapersOpen AccessThe NHGRI-EBI GWAS Catalog: standards for reusability, sustainability and diversity
The NHGRI-EBI GWAS Catalog serves as a vital resource for the genetic research community, providing access to the most comprehensive database of human GWAS results. Currently, it contains close to 7 000 publications for >15 000 traits, from which more than 625 000 lead associations have been curated. Additionally, 85 000 full genome-wide summary statistics datasets—containing association data for all variants in the analysis—are available for downstream analyses such as meta-analysis, fine-mapping, Mendelian randomisation or development of polygenic risk scores. As a centralised repository for GWAS results, the GWAS Catalog sets and implements standards for data submission and harmonisation, and encourages the use of consistent descriptors for traits, samples and methodologies. We share processes and vocabulary with the PGS Catalog, improving interoperability for a growing user group. Here, we describe the latest changes in data content, improvements in our user interface, and the implementation of the GWAS-SSF standard format for summary statistics. We address the challenges of handling the rapid increase in large-scale molecular quantitative trait GWAS and the need for sensitivity in the use of population and cohort descriptors while maintaining data interoperability and reusability.
- Open Access
The NHGRI-EBI GWAS Catalog: standards for reusability, sustainability and diversity
The NHGRI-EBI GWAS Catalog serves as a vital resource for the genetic research community, providing access to the most comprehensive database of human GWAS results. Currently, it contains close to 7,000 publications for more than 15,000 traits, from which more than 625,000 lead associations have been curated. Additionally, 85,000 full genome-wide summary statistics datasets - containing association data for all variants in the analysis - are available for downstream analyses such as meta-analysis, fine-mapping, Mendelian randomisation or development of polygenic risk scores. As a centralised repository for GWAS results, the GWAS Catalog sets and implements standards for data submission and harmonisation, and encourages the use of consistent descriptors for traits, samples and methodologies. We share processes and vocabulary with the PGS Catalog, improving interoperability for a growing user group. Here, we describe the latest changes in data content, improvements in our user interface, and the implementation of the GWAS-SSF standard format for summary statistics. We address the challenges of handling the rapid increase in large-scale molecular quantitative trait GWAS and the need for sensitivity in the use of population and cohort descriptors while maintaining data interoperability and reusability.
Open AccessThe NHGRI-EBI GWAS Catalog: standards for reusability, sustainability and diversity
The NHGRI-EBI GWAS Catalog serves as a vital resource for the genetic research community, providing access to the most comprehensive database of human GWAS results. Currently, it contains close to 7,000 publications for more than 15,000 traits, from which more than 625,000 lead associations have been curated. Additionally, 85,000 full genome-wide summary statistics datasets - containing association data for all variants in the analysis - are available for downstream analyses such as meta-analysis, fine-mapping, Mendelian randomisation or development of polygenic risk scores. As a centralised repository for GWAS results, the GWAS Catalog sets and implements standards for data submission and harmonisation, and encourages the use of consistent descriptors for traits, samples and methodologies. We share processes and vocabulary with the PGS Catalog, improving interoperability for a growing user group. Here, we describe the latest changes in data content, improvements in our user interface, and the implementation of the GWAS-SSF standard format for summary statistics. We address the challenges of handling the rapid increase in large-scale molecular quantitative trait GWAS and the need for sensitivity in the use of population and cohort descriptors while maintaining data interoperability and reusability.
- Top Cited Papers
- 26 September 2024
- Published by Springer Nature in Nature Genetics
- Vol. 56 (10) , 1989-1994
Enhancing the Polygenic Score Catalog with tools for score calculation and ancestry normalization
Polygenic scores (PGSs) have transformed human genetic research and have numerous potential clinical applications. Here we present a series of recent enhancements to the PGS Catalog and highlight the PGS Catalog Calculator, an open-source, scalable and portable pipeline for reproducibly calculating PGSs that democratizes equitable PGS applications.
- 26 September 2024
- Published by Springer Nature in Nature Genetics
- Vol. 56 (10) , 1989-1994
Top Cited PapersEnhancing the Polygenic Score Catalog with tools for score calculation and ancestry normalization
Polygenic scores (PGSs) have transformed human genetic research and have numerous potential clinical applications. Here we present a series of recent enhancements to the PGS Catalog and highlight the PGS Catalog Calculator, an open-source, scalable and portable pipeline for reproducibly calculating PGSs that democratizes equitable PGS applications.
- Open Access
The Polygenic Score Catalog: new functionality and tools to enable FAIR research
Polygenic scores (PGS) have transformed human genetic research and have multiple potential clinical applications, including risk stratification for disease prevention and prediction of treatment response. Here, we present a series of recent enhancements to the PGS Catalog ( www.PGSCatalog.org ), the largest findable, accessible, interoperable, and reusable (FAIR) repository of PGS. These include expansions in data content and ancestral diversity as well as the addition of new features. We further present the PGS Catalog Calculator ( pgsc_calc , https://github.com/PGScatalog/pgsc_calc ), an open-source, scalable and portable pipeline to reproducibly calculate PGS that securely democratizes equitable PGS applications by implementing genetic ancestry estimation and score normalization using reference data. With the PGS Catalog & calculator users can now quantify an individual’s genetic predisposition for hundreds of common diseases and clinically relevant traits. Taken together, these updates and tools facilitate the next generation of PGS, thus lowering barriers to the clinical studies necessary to identify where PGS may be integrated into clinical practice.
Open AccessThe Polygenic Score Catalog: new functionality and tools to enable FAIR research
Polygenic scores (PGS) have transformed human genetic research and have multiple potential clinical applications, including risk stratification for disease prevention and prediction of treatment response. Here, we present a series of recent enhancements to the PGS Catalog ( www.PGSCatalog.org ), the largest findable, accessible, interoperable, and reusable (FAIR) repository of PGS. These include expansions in data content and ancestral diversity as well as the addition of new features. We further present the PGS Catalog Calculator ( pgsc_calc , https://github.com/PGScatalog/pgsc_calc ), an open-source, scalable and portable pipeline to reproducibly calculate PGS that securely democratizes equitable PGS applications by implementing genetic ancestry estimation and score normalization using reference data. With the PGS Catalog & calculator users can now quantify an individual’s genetic predisposition for hundreds of common diseases and clinically relevant traits. Taken together, these updates and tools facilitate the next generation of PGS, thus lowering barriers to the clinical studies necessary to identify where PGS may be integrated into clinical practice.
- Open Access
Evaluation of polygenic scoring methods in five biobanks reveals greater variability between biobanks than between methods and highlights benefits of ensemble learning
Methods to estimate polygenic scores (PGS) from genome-wide association studies are increasingly utilized. However, independent method evaluation is lacking, and method comparisons are often limited. Here, we evaluate polygenic scores derived using seven methods in five biobank studies (totaling about 1.2 million participants) across 16 diseases and quantitative traits, building on a reference-standardized framework. We conducted meta-analyses to quantify the effects of method choice, hyperparameter tuning, method ensembling and target biobank on PGS performance. We found that no single method consistently outperformed all others. PGS effect sizes were more variable between biobanks than between methods within biobanks when methods were well-tuned. Differences between methods were largest for the two investigated autoimmune diseases, seropositive rheumatoid arthritis and type 1 diabetes. For most methods, cross-validation was more reliable for tuning hyperparameters than automatic tuning (without the use of target data). For a given target phenotype, elastic net models combining PGS across methods (ensemble PGS) tuned in the UK Biobank provided consistent, high, and cross-biobank transferable performance, increasing PGS effect sizes (β-coefficients) by a median of 5.0% relative to LDpred2 and MegaPRS (the two best performing single methods when tuned with cross-validation). Our interactively browsable online-results ( https://methodscomparison.intervenegeneticscores.org/ ) and open-source workflow prspipe ( https://github.com/intervene-EU-H2020/prspipe ) provide a rich resource and reference for the analysis of polygenic scoring methods across biobanks.
Open AccessEvaluation of polygenic scoring methods in five biobanks reveals greater variability between biobanks than between methods and highlights benefits of ensemble learning
Methods to estimate polygenic scores (PGS) from genome-wide association studies are increasingly utilized. However, independent method evaluation is lacking, and method comparisons are often limited. Here, we evaluate polygenic scores derived using seven methods in five biobank studies (totaling about 1.2 million participants) across 16 diseases and quantitative traits, building on a reference-standardized framework. We conducted meta-analyses to quantify the effects of method choice, hyperparameter tuning, method ensembling and target biobank on PGS performance. We found that no single method consistently outperformed all others. PGS effect sizes were more variable between biobanks than between methods within biobanks when methods were well-tuned. Differences between methods were largest for the two investigated autoimmune diseases, seropositive rheumatoid arthritis and type 1 diabetes. For most methods, cross-validation was more reliable for tuning hyperparameters than automatic tuning (without the use of target data). For a given target phenotype, elastic net models combining PGS across methods (ensemble PGS) tuned in the UK Biobank provided consistent, high, and cross-biobank transferable performance, increasing PGS effect sizes (β-coefficients) by a median of 5.0% relative to LDpred2 and MegaPRS (the two best performing single methods when tuned with cross-validation). Our interactively browsable online-results ( https://methodscomparison.intervenegeneticscores.org/ ) and open-source workflow prspipe ( https://github.com/intervene-EU-H2020/prspipe ) provide a rich resource and reference for the analysis of polygenic scoring methods across biobanks.
- Top Cited PapersOpen Access
- 9 November 2022
- Published by Oxford University Press (OUP) in Nucleic Acids Research
- Vol. 51 (D1) , D977-D985
The NHGRI-EBI GWAS Catalog: knowledgebase and deposition resource
The NHGRI-EBI GWAS Catalog (www.ebi.ac.uk/gwas) is a FAIR knowledgebase providing detailed, structured, standardised and interoperable genome-wide association study (GWAS) data to >200 000 users per year from academic research, healthcare and industry. The Catalog contains variant-trait associations and supporting metadata for >45 000 published GWAS across >5000 human traits, and >40 000 full P-value summary statistics datasets. Content is curated from publications or acquired via author submission of prepublication summary statistics through a new submission portal and validation tool. GWAS data volume has vastly increased in recent years. We have updated our software to meet this scaling challenge and to enable rapid release of submitted summary statistics. The scope of the repository has expanded to include additional data types of high interest to the community, including sequencing-based GWAS, gene-based analyses and copy number variation analyses. Community outreach has increased the number of shared datasets from under-represented traits, e.g. cancer, and we continue to contribute to awareness of the lack of population diversity in GWAS. Interoperability of the Catalog has been enhanced through links to other resources including the Polygenic Score Catalog and the International Mouse Phenotyping Consortium, refinements to GWAS trait annotation, and the development of a standard format for GWAS data.
- 9 November 2022
- Published by Oxford University Press (OUP) in Nucleic Acids Research
- Vol. 51 (D1) , D977-D985
Top Cited PapersOpen AccessThe NHGRI-EBI GWAS Catalog: knowledgebase and deposition resource
The NHGRI-EBI GWAS Catalog (www.ebi.ac.uk/gwas) is a FAIR knowledgebase providing detailed, structured, standardised and interoperable genome-wide association study (GWAS) data to >200 000 users per year from academic research, healthcare and industry. The Catalog contains variant-trait associations and supporting metadata for >45 000 published GWAS across >5000 human traits, and >40 000 full P-value summary statistics datasets. Content is curated from publications or acquired via author submission of prepublication summary statistics through a new submission portal and validation tool. GWAS data volume has vastly increased in recent years. We have updated our software to meet this scaling challenge and to enable rapid release of submitted summary statistics. The scope of the repository has expanded to include additional data types of high interest to the community, including sequencing-based GWAS, gene-based analyses and copy number variation analyses. Community outreach has increased the number of shared datasets from under-represented traits, e.g. cancer, and we continue to contribute to awareness of the lack of population diversity in GWAS. Interoperability of the Catalog has been enhanced through links to other resources including the Polygenic Score Catalog and the International Mouse Phenotyping Consortium, refinements to GWAS trait annotation, and the development of a standard format for GWAS data.
- Open Access
- 13 October 2021
- Published by Elsevier in Cell Genomics
- Vol. 1 (1)
Sequencing-based genome-wide association studies reporting standards
- 13 October 2021
- Published by Elsevier in Cell Genomics
- Vol. 1 (1)
Open AccessSequencing-based genome-wide association studies reporting standards